Boehringer Ingelheim Clinical Trials: 2,282 Led Studies

Archive historyOct 2022 to Jul 2026

144 recorded changes across Boehringer Ingelheim trials

Every status move, completion date shift and enrollment change ComplyRx has recorded across 37 of these trials. One is shown below.

Status changeStatus moved to active not recruiting from recruitingNCT06241560 · recorded 14 Jul 2026

Track to read them

+140 more recorded changes · Track a drug to see every change the night it lands

Track nerandomilast

Most active programmes

The drugs appearing most often across Boehringer Ingelheim's recently active trials. Comparator arms are excluded.

BI 7641986 trials
Zongertinib5 trials
Nerandomilast5 trials
Empagliflozin5 trials
Carboplatin4 trials
BI 7645324 trials

Upcoming readouts

Next primary completion dates among Boehringer Ingelheim's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.

Mar 2027A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic P…Phase 2
Apr 2027FIBRONEER™-ON: A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibros…Phase 3
Jun 2027A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due t…Phase 2
Jul 2027A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseas…Phase 3
Jul 2027A Study to Test Whether BI 3032950 Helps People With Ulcerative ColitisPhase 2
Aug 2027A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweig…Phase 2

Top therapeutic areas

Conditions studied most often across Boehringer Ingelheim's recently active trials.

Obesity7 trials
Solid Tumors4 trials
Idiopathic Pulmonary Fibrosis3 trials
Interstitial Lung Diseases3 trials
Diabetes Mellitus, Type 23 trials
Chronic Kidney Disease3 trials

Boehringer Ingelheim trials

The 50 most significant of Boehringer Ingelheim's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.

Trial	Phase	Stability	Status	Enrollment	Est. readout
A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated FlaresNCT06013969Spesolimab	Phase 4	Locked · track to reveal	OngoingActive, not recruiting	42 est.	23 Jul 2026
A Study in Healthy People to Test How Vicadrostat Affects the HeartNCT07513207Vicadrostat	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	45 est.	24 Jul 2026
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodNCT06241560BI 1015550	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	20 est.	4 Aug 2026
A Study to Test How Verducatib is Taken up in the Body of Healthy Chinese ParticipantsNCT07531628Verducatib	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	9 est.	10 Aug 2026
A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity DisorderNCT07001475BI 3031185	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	78 est.	11 Aug 2026
A Study in Healthy Men to Test How Bosentan Influences the Amount of Zongertinib in the BloodNCT07649941Zongertinib	Phase 1	Not yet scored	OngoingRecruiting	16 est.	19 Aug 2026
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney DiseaseNCT06926660Vicadrostat	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	492 est.	20 Aug 2026
A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3NCT04429087Obrixtamig - parenteral 1	Phase 1	Locked · track to reveal	OngoingRecruiting	300 est.	1 Sept 2026
DAREONᵀᴹ-8DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung CancerNCT06077500BI 764532	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	46 est.	1 Sept 2026
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard TreatmentNCT06151574zongertinib	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	428 est.	2 Sept 2026
A Study in Healthy Men to Test How BI 1815368 is Processed in the BodyNCT07693218BI 1815368 (C-14)	Phase 1	Not yet scored	OngoingNot yet recruiting	10 est.	5 Sept 2026
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver ProblemsNCT07023354BI 1291583	Phase 1	Locked · track to reveal	OngoingRecruiting	32 est.	17 Sept 2026
A Study to Test How BI 3034701 is Taken up and Processed by the Body in Healthy Men With Normal Weight or OverweightNCT07708493BI 3034701 (C-14)	Phase 1	Not yet scored	OngoingNot yet recruiting	8 est.	14 Oct 2026
Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United StatesNCT07342309	—	Not yet scored	OngoingActive, not recruiting	7,933 est.	30 Oct 2026
A Study in Japanese Healthy Men to Test How Well Different Doses of BI 3031185 Are Tolerated and a Study in Japanese Healthy Women to Test Whether BI 3031185 Influences the Amount of a Contraceptive in the BloodNCT07656792BI 3031185	Phase 1	Not yet scored	OngoingNot yet recruiting	36 est.	26 Nov 2026
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the LiverNCT05202353BI 456906	Phase 1	Locked · track to reveal	OngoingRecruiting	30 est.	2 Dec 2026
A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 InterferonopathiesNCT06878365BI 3000202_low dose	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	16 est.	6 Dec 2026
A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or OverweightNCT07693231BI 3034701	Phase 1	Not yet scored	OngoingNot yet recruiting	48 est.	22 Dec 2026
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)NCT04886804zongertinib	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	608 est.	30 Dec 2026
A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the BodyNCT07407348Formulation A	Phase 1	Locked · track to reveal	OngoingRecruiting	80 est.	26 Jan 2027
A Study in Healthy Men to Test How Well Different Doses of BI 3776528 Are ToleratedNCT06745297BI 3776528	Phase 1	Locked · track to reveal	OngoingRecruiting	172 est.	3 Feb 2027
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic RetinopathyNCT06321302BI 764524	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	190 est.	5 Mar 2027
A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal AdenocarcinomaNCT05846516VSV-GP154	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	59 est.	8 Mar 2027
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard TreatmentNCT07036523BI 765423	Phase 2	Locked · track to reveal	OngoingRecruiting	71 est.	11 Mar 2027
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are ToleratedNCT07553429Low dose BI 3812465	Phase 1	Locked · track to reveal	OngoingRecruiting	49 est.	23 Mar 2027
DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent ChemotherapyNCT05990738BI 764532	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	69 est.	30 Mar 2027
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This MedicineNCT05846230BI 1291583	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	268 est.	31 Mar 2027
FIBRONEER™-ONA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastNCT06238622Nerandomilast	Phase 3	Locked · track to reveal	OngoingRecruiting	1,700 est.	28 Apr 2027
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)NCT07325526BI 3802876	Phase 2	Locked · track to reveal	OngoingRecruiting	29 est.	29 Jun 2027
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic DiseasesNCT06806592Nerandomilast	Phase 3	Locked · track to reveal	OngoingRecruiting	400 est.	17 Jul 2027
A Study to Test Whether BI 3032950 Helps People With Ulcerative ColitisNCT06636656BI 3032950 intravenous (Part A)	Phase 2	Locked · track to reveal	OngoingRecruiting	80 est.	30 Jul 2027
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or OverweightNCT07662122BI 3034701	Phase 2	Not yet scored	OngoingRecruiting	300 est.	4 Aug 2027
A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3NCT05916313BI 764532	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	20 est.	9 Aug 2027
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without PembrolizumabNCT07486817Zongertinib	Phase 2	Locked · track to reveal	OngoingRecruiting	60 est.	12 Aug 2027
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab AloneNCT06806852BI 770371	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	91 est.	31 Aug 2027
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular EdemaNCT06962839BI 1815368	Phase 2	Locked · track to reveal	OngoingRecruiting	300 est.	1 Sept 2027
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine CancersNCT05882058BI 764532, dose 1	Phase 2	Locked · track to reveal	OngoingRecruiting	204 est.	1 Sept 2027
TENACITYA Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen WellNCT07361302Tenecteplase	Phase 3	Locked · track to reveal	OngoingRecruiting	1,325 est.	2 Oct 2027
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine CancersNCT06132113BI 764532	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	65 est.	9 Oct 2027
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma GangrenosumNCT06624670Spesolimab	Phase 3	Locked · track to reveal	OngoingRecruiting	90 est.	12 Nov 2027
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)NCT05155332BI 1831169	Phase 1	Locked · track to reveal	OngoingSuspended	190 est.	13 Dec 2027
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 AlterationsNCT06581432Zongertinib	Phase 2	Locked · track to reveal	OngoingRecruiting	430 est.	31 Dec 2027
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney DiseaseNCT07355296BI 764198	Phase 2	Locked · track to reveal	OngoingRecruiting	132 est.	20 Jan 2028
A Study to Test How Well Different Doses of BI 3804379 Are Tolerated by Healthy People and Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH)NCT06575400BI 3804379	Phase 1	Locked · track to reveal	OngoingRecruiting	124 est.	2 Feb 2028
A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)NCT07395258BI 3923948	Phase 1	Locked · track to reveal	OngoingSuspended	60 est.	20 Feb 2028
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailureNCT06424288vicadrostat	Phase 3	Locked · track to reveal	OngoingRecruiting	6,000 est.	22 May 2028
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With EzabenlimabNCT07607678BI 3819026	Phase 1	Locked · track to reveal	OngoingRecruiting	60 est.	5 Jun 2028
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)NCT07107945Empagliflozin	Phase 3	Locked · track to reveal	OngoingRecruiting	120 est.	26 Jun 2028
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)NCT06531824BI 690517	Phase 3	Locked · track to reveal	OngoingRecruiting	11,000 est.	30 Aug 2028
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemotherapyNCT07472517obrixtamig	Phase 3	Locked · track to reveal	OngoingRecruiting	670 est.	9 Sept 2028

View all trials2,282

A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares

Phase 4Active, not recruitingNCT06013969 ↗

Primary completion: Jul 2026; estimated
Enrollment: 42; estimated
Start: Oct 2023; Boehringer Ingelheim

Conditions

Generalized Pustular Psoriasis

Interventions

Spesolimab

Brief summary

This study is open to adults with a serious skin disease called generalized pustular psoriasis (GPP) who have repeated flares of GPP. The purpose of this study is to find out whether a medicine called spesolimab helps people with repeated flares of GPP. Participants are given a single dose of spesolimab as an…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Oct 2024

Status change · 2

Completion date move · 1

Enrollment change · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

Phase 2Active, not recruitingNCT06241560 ↗

Primary completion: Aug 2026; estimated
Enrollment: 20; estimated
Start: Mar 2026; Boehringer Ingelheim

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

BI 1015550
Pirfenidone

Brief summary

This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are 40 years and older. The purpose of this study is to find out whether a medicine called pirfenidone changes the amount of a medicine called BI 1015550 in the blood. Some people may take more than one medicine at a time. Therefore, it is…

Full record on ClinicalTrials.gov ↗

Change timeline

7 recorded · latest 14 Jul 2026

Completion date move · 4

Status change · 2

Enrollment change · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder

Phase 1Active, not recruitingNCT07001475 ↗

Primary completion: Aug 2026; estimated
Enrollment: 78; estimated
Start: Aug 2025; Boehringer Ingelheim

Conditions

Borderline Personality Disorder
Attention Deficit Hyperactivity Disorder

Interventions

BI 3031185
Placebo

Brief summary

This study is open to adults with certain mental health conditions. The purpose of this study is to find out how a medicine called BI 3031185 is tolerated by people with certain mental health conditions. Participants are put into 2 groups of equal size randomly, which means by chance. Group 1 takes a single dose of…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Feb 2026

Completion date move · 1

Status change · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

Phase 2Active, not recruitingNCT06926660 ↗

Primary completion: Aug 2026; estimated
Enrollment: 492; estimated
Start: Jul 2025; Boehringer Ingelheim

Conditions

Chronic Kidney Disease

Interventions

Vicadrostat
Empagliflozin
Placebo matching vicadrostat

Brief summary

This study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a specific type of medication for kidney disease called SGLT2 inhibitor within 1 month before the study or have certain health conditions cannot take part in this study. The purpose of this study is…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Jun 2026

Status change · 2

Enrollment change · 1

Completion date move · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Phase 1RecruitingNCT04429087 ↗

Primary completion: Sept 2026; estimated
Enrollment: 300; estimated
Start: Jul 2020; Boehringer Ingelheim

Conditions

Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3

Interventions

Obrixtamig - parenteral 1
Obrixtamig - parenteral 2

Brief summary

This study is open to adults with small cell lung cancer and other neuroendocrine cancers that are positive for the tumour marker delta-like 3 (DLL3). The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find out…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Nov 2025

Completion date move · 3

Enrollment change · 2

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

DAREONᵀᴹ-8: DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer

Phase 1Active, not recruitingNCT06077500 ↗

Primary completion: Sept 2026; estimated
Enrollment: 46; estimated
Start: Feb 2024; Boehringer Ingelheim

Conditions

Small Cell Lung Carcinoma (SCLC)

Interventions

BI 764532
Carboplatin
Etoposide
Atezolizumab

Brief summary

This study is open to adults with extensive stage small cell lung cancer. The study is in people with advanced cancer that are eligible for standard of care including chemotherapy and anti-PD-L1 (Programmed Cell Death Ligand 1) immunotherapy. The purpose of this study is to find out the highest dose of BI 764532…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Jan 2026

Completion date move · 2

Status change · 2

Enrollment change · 2

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Phase 3Active, not recruitingNCT06151574 ↗

Primary completion: Sept 2026; estimated
Enrollment: 428; estimated
Start: Feb 2024; Boehringer Ingelheim

Conditions

Lung Cancer, Non-squamous, Non-small Cell

Interventions

zongertinib
pembrolizumab
cisplatin
carboplatin
pemetrexed

Brief summary

This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including chemotherapy for advanced or metastatic lung cancer. The purpose of this study is to find…

Full record on ClinicalTrials.gov ↗

Change timeline

7 recorded · latest 1 May 2026

Completion date move · 3

Status change · 2

Enrollment change · 2

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems

Phase 1RecruitingNCT07023354 ↗

Primary completion: Sept 2026; estimated
Enrollment: 32; estimated
Start: Jul 2025; Boehringer Ingelheim

Conditions

Healthy
Hepatic Impairment

Interventions

BI 1291583

Brief summary

This study is open to adults aged between 18 and 80 years of age with a body mass index (BMI) of 18.5 to 42 kg/m². People with or without liver problems can take part in the study. The purpose of this study is to find out how much of a medicine called BI 1291583 gets into the blood of people with and without liver…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Feb 2026

Completion date move · 1

Status change · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

A Study in Japanese Healthy Men to Test How Well Different Doses of BI 3031185 Are Tolerated and a Study in Japanese Healthy Women to Test Whether BI 3031185 Influences the Amount of a Contraceptive in the Blood

Phase 1Not yet recruitingNCT07656792 ↗

Primary completion: Nov 2026; estimated
Enrollment: 36; estimated
Start: Jul 2026; Boehringer Ingelheim

Conditions

Healthy

Interventions

BI 3031185
Placebo matching BI 3031185
Midazolam
YAZ®

Brief summary

Single dose (SD) part: The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3031185 in healthy male trial participants following oral administration of single dose. Multiple doses (MD) part: The main objectives of this trial are to investigate safety, tolerability…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver

Phase 1RecruitingNCT05202353 ↗

Primary completion: Dec 2026; estimated
Enrollment: 30; estimated
Start: Oct 2024; Boehringer Ingelheim

Conditions

Obesity

Interventions

BI 456906
Semaglutide

Brief summary

This study is open to adults with obesity. People with a body mass index (BMI) in the range from 30 to 40 kg/m2 and a body weight of 70 to 150 kg can participate in the study. The purpose of this study is to find out whether treatment with a medicine called BI 456906 changes the occupancy of receptors in the liver and…

Full record on ClinicalTrials.gov ↗

Change timeline

9 recorded · latest 1 Oct 2025

Completion date move · 7

Status change · 1

Enrollment change · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies

Phase 1Active, not recruitingNCT06878365 ↗

Primary completion: Dec 2026; estimated
Enrollment: 16; estimated
Start: Jul 2025; Boehringer Ingelheim

Conditions

Type 1 Interferonopathies

Interventions

BI 3000202_low dose
BI 3000202_high dose

Brief summary

This study is open to adults with selected type 1 interferonopathies. People can join the study if they have Aicardi-Goutières syndrome (AGS), Coatomer subunit alpha (COPA) syndrome, Familial chilblain lupus (FCL), or another type 1 interferonopathy with a specific gene mutation. The purpose of this study is to find…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Apr 2026

Status change · 2

Enrollment change · 1

Completion date move · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Phase 1Active, not recruitingNCT04886804 ↗

Primary completion: Dec 2026; estimated
Enrollment: 608; estimated
Start: Jul 2021; Boehringer Ingelheim

Conditions

Neoplasm Metastasis
Non-Small Cell Lung Cancer

Interventions

zongertinib

Brief summary

The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful. The second part is open to people with non-small cell lung cancer with a specific mutation in the HER2 gene. The purpose of the…

Full record on ClinicalTrials.gov ↗

Change timeline

9 recorded · latest 1 Apr 2026

Enrollment change · 4

Completion date move · 4

Status change · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

Phase 2Active, not recruitingNCT06321302 ↗

Primary completion: Mar 2027; estimated
Enrollment: 190; estimated
Start: May 2024; Boehringer Ingelheim

Conditions

Diabetic Retinopathy

Interventions

BI 764524
Sham comparator to BI 764524
Aflibercept (Eylea®) - US only

Brief summary

This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join the study. The purpose of this study is to find out whether a medicine called BI 764524 helps people with diabetic retinopathy. The study also aims to find a suitable…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 May 2026

Status change · 2

Completion date move · 2

Enrollment change · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma

Phase 1Active, not recruitingNCT05846516 ↗

Primary completion: Mar 2027; estimated
Enrollment: 59; estimated
Start: May 2023; Boehringer Ingelheim

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

VSV-GP154
ATP150
ATP152
Ezabenlimab
ATP162

Brief summary

This study has stopped recruitment. Adults with advanced pancreatic cancer participate in this study. The study tests a type of immunotherapy. It is a protein treatment (ATP150/ATP152/ATP162) combined with a virus (VSV-GP154) that may kill cancer cells and help the immune system fight cancer. The immunotherapy is…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Mar 2026

Completion date move · 3

Enrollment change · 2

Status change · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

Phase 2RecruitingNCT07036523 ↗

Primary completion: Mar 2027; estimated
Enrollment: 71; estimated
Start: Nov 2025; Boehringer Ingelheim

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

BI 765423
Placebo

Brief summary

This study is open to adults who are at least 40 years old and have idiopathic pulmonary fibrosis (IPF). People can participate in the study if they have a forced vital capacity (FVC) greater than or equal to 45% of the predicted value and fibrosis of 20% or more confirmed by a high-resolution computed tomography…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jan 2026

Status change · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy

Phase 1Active, not recruitingNCT05990738 ↗

Primary completion: Mar 2027; estimated
Enrollment: 69; estimated
Start: Feb 2024; Boehringer Ingelheim

Conditions

Small Cell Lung Carcinoma (SCLC)

Interventions

BI 764532
Topotecan
Single agent chemotherapy

Brief summary

This study is open to adults with extensive stage small cell lung cancer. The study is in people with advanced cancer that had previously received platinum-based chemotherapy and are eligible to receive a single agent chemotherapy treatment. The purpose of this study is to find the highest dose of BI 764532 that…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Apr 2026

Enrollment change · 3

Status change · 2

Completion date move · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

Phase 2Active, not recruitingNCT05846230 ↗

Primary completion: Mar 2027; estimated
Enrollment: 268; estimated
Start: Sept 2023; Boehringer Ingelheim

Conditions

Bronchiectasis

Interventions

BI 1291583
Placebo matching BI 1291583

Brief summary

This study is open to adults aged 18 years and older with bronchiectasis. People can join the study if they were previously enrolled in another study with BI 1291583 (1397-0012: Airleafᵀᴹ or 1397-0013 Clairaflyᵀᴹ). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Jul 2025

Enrollment change · 2

Status change · 2

Completion date move · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

FIBRONEER™-ON: A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

Phase 3RecruitingNCT06238622 ↗

Primary completion: Apr 2027; estimated
Enrollment: 1,700; estimated
Start: May 2024; Boehringer Ingelheim

Conditions

Idiopathic Pulmonary Fibrosis
Progressive Pulmonary Fibrosis

Interventions

Nerandomilast

Brief summary

This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550. The goal of this study is to find out how well people with pulmonary fibrosis…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Oct 2024

Status change · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

Phase 2RecruitingNCT07325526 ↗

Primary completion: Jun 2027; estimated
Enrollment: 29; estimated
Start: Feb 2026; Boehringer Ingelheim

Conditions

Liver Cirrhosis

Interventions

BI 3802876
Placebo

Brief summary

This study is open to adults with a type of confirmed liver condition called compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH). The purpose of this study is to find out how well a study medicine called BI 3802876 is tolerated in people with this condition. The study looks at how…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Apr 2026

Status change · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases

Phase 3RecruitingNCT06806592 ↗

Primary completion: Jul 2027; estimated
Enrollment: 400; estimated
Start: Sept 2025; Boehringer Ingelheim

Conditions

Interstitial Lung Diseases
Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases

Interventions

Nerandomilast
Placebo matching nerandomilast

Brief summary

Adults 18 years of age and older or above legal age with lung fibrosis related to systemic autoimmune rheumatic disease can participate in this study. People can only take part if they show no improvement in lung function after standard treatment with immunosuppressant medicine. The main purpose of this study is to…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Oct 2025

Status change · 1

Completion date move · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis

Phase 2RecruitingNCT06636656 ↗

Primary completion: Jul 2027; estimated
Enrollment: 80; estimated
Start: Dec 2024; Boehringer Ingelheim

Conditions

Ulcerative Colitis

Interventions

BI 3032950 intravenous (Part A)
BI 3032950 subcutaneous (Part B)

Brief summary

Adults between 18 and 80 years of age with ulcerative colitis can participate in this study. This is a study for people for whom previous treatment was not successful or who stopped previous treatment. The purpose of this study is to find out whether BI 3032950 helps people with ulcerative colitis. This study has 2…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Mar 2026

Completion date move · 2

Enrollment change · 1

Status change · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

Phase 1Active, not recruitingNCT05916313 ↗

Primary completion: Aug 2027; estimated
Enrollment: 20; estimated
Start: Jan 2024; Boehringer Ingelheim

Conditions

Glioma

Interventions

BI 764532

Brief summary

This study (1438-0003) is open to adults with a tumour in the brain that is positive for the tumour marker delta-like 3 (DLL3). This study is in people with advanced cancer for whom previous treatment was not successful. The purpose of this study is to find out the highest dose of BI 764532 that people with a brain…

Full record on ClinicalTrials.gov ↗

Change timeline

9 recorded · latest 1 Apr 2026

Completion date move · 5

Status change · 2

Enrollment change · 2

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

Phase 2RecruitingNCT07486817 ↗

Primary completion: Aug 2027; estimated
Enrollment: 60; estimated
Start: Jun 2026; Boehringer Ingelheim

Conditions

Lung Cancer, Non-squamous, Non-small Cell

Interventions

Zongertinib
Cisplatin
Carboplatin
Pemetrexed
Pembrolizumab

Brief summary

This study is open to adults with a type of lung cancer called HER2-mutant non-squamous non-small cell lung cancer (NSCLC) that is advanced or has spread. People who have a tumor with a HER2 mutation and have not received previous treatment for their lung cancer can participate in the study. The purpose of this study…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

Phase 1Active, not recruitingNCT06806852 ↗

Primary completion: Aug 2027; estimated
Enrollment: 91; estimated
Start: May 2025; Boehringer Ingelheim

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

BI 770371
Pembrolizumab
Cetuximab

Brief summary

This study is open to adults with head and neck cancer. The purpose of this study is to find out whether combining different study medicines makes tumors shrink in people with head and neck cancer. The tested medicines in this study are antibodies that act in different ways against cancer. BI 770371 and pembrolizumab…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Jun 2026

Completion date move · 3

Status change · 2

Enrollment change · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Phase 2RecruitingNCT05882058 ↗

Primary completion: Sept 2027; estimated
Enrollment: 204; estimated
Start: Oct 2023; Boehringer Ingelheim

Conditions

Small Cell Lung Carcinoma
Neuroendocrine Neoplasms
Extra-pulmonary Neuroendocrine Carcinoma

Interventions

BI 764532, dose 1
BI 764532, dose 2
Ventana DLL3 RxDx assay

Brief summary

This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find a suitable dose of BI 764532 (also called obrixtamig) that people…

Full record on ClinicalTrials.gov ↗

Change timeline

9 recorded · latest 1 May 2026

Completion date move · 4

Status change · 3

Enrollment change · 2

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

TENACITY: A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

Phase 3RecruitingNCT07361302 ↗

Primary completion: Oct 2027; estimated
Enrollment: 1,325; estimated
Start: Feb 2026; Boehringer Ingelheim

Conditions

Acute Ischemic Stroke

Interventions

Tenecteplase
Standard of care treatment

Brief summary

This study is open to adults who had an acute stroke caused by a clot blocking a blood vessel in the brain (acute ischemic stroke). This study is for people who had an acute stroke or woke up with a stroke and were last seen well more than 4.5 hours before joining the study. Participants need to have imaging that…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Apr 2026

Status change · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Phase 1Active, not recruitingNCT06132113 ↗

Primary completion: Oct 2027; estimated
Enrollment: 65; estimated
Start: Jan 2024; Boehringer Ingelheim

Conditions

Neuroendocrine Neoplasms

Interventions

BI 764532
Carboplatin
Etoposide
Cisplatin

Brief summary

This study is open to adults aged 18 and older or above legal age who have a specific type of advanced neuroendocrine cancer (NEC). Their tumours must be positive for a marker called DLL3. The purpose of this study is to test a medicine called BI 764532 in addition to chemotherapy. The study has Part A1, Part A2, and…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Dec 2025

Completion date move · 3

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

Phase 3RecruitingNCT06624670 ↗

Primary completion: Nov 2027; estimated
Enrollment: 90; estimated
Start: Feb 2025; Boehringer Ingelheim

Conditions

Pyoderma Gangrenosum

Interventions

Spesolimab
Placebo matching to spesolimab
Prednisone
Prednisolone

Brief summary

The purpose of this study is to find out whether a medicine called spesolimab helps people with pyoderma gangrenosum (PG). The main aim is to see whether spesolimab leads to closure of PG ulcers. This study is open to adults with ulcerative PG with at least 1 ulcer that measures between 5 cm\^2 to 80 cm\^2 in…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 May 2026

Completion date move · 2

Status change · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

Phase 1SuspendedNCT05155332 ↗

Primary completion: Dec 2027; estimated
Enrollment: 190; estimated
Start: Mar 2022; Boehringer Ingelheim

Conditions

Solid Tumors

Interventions

BI 1831169
anti-PD-1 antibody

Brief summary

This study is open to adults with different types of advanced cancer (solid tumors) that are accessible for injection and/or biopsy. This is a study for people with a life expectancy of at least 3 months after starting study treatment. The purpose of this study is to find the highest dose of a medicine called BI…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Jun 2026

Completion date move · 3

Status change · 1

Enrollment change · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

Phase 2RecruitingNCT06581432 ↗

Primary completion: Dec 2027; estimated
Enrollment: 430; estimated
Start: Oct 2024; Boehringer Ingelheim

Conditions

Solid Tumours

Interventions

Zongertinib

Brief summary

This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of this study is to find out whether a medicine called zongertinib helps people with advanced cancers with HER2 alterations.…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Sept 2025

Enrollment change · 1

Completion date move · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

Phase 2RecruitingNCT07355296 ↗

Primary completion: Jan 2028; estimated
Enrollment: 132; estimated
Start: Mar 2026; Boehringer Ingelheim

Conditions

Proteinuric Kidney Diseases

Interventions

BI 764198
Placebo matching BI 764198

Brief summary

This study is open to adults with certain kidney conditions, including secondary focal segmental glomerulosclerosis (sFSGS), treatment-resistant primary minimal change disease (TR-pMCD), Alport Syndrome (AS), and treatment-resistant primary membranous nephropathy (TR-pMN). Adolescents with treatment-resistant primary…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 May 2026

Status change · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

A Study to Test How Well Different Doses of BI 3804379 Are Tolerated by Healthy People and Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH)

Phase 1RecruitingNCT06575400 ↗

Primary completion: Feb 2028; estimated
Enrollment: 124; estimated
Start: Sept 2024; Boehringer Ingelheim

Conditions

Healthy
Metabolic Dysfunction-associated Steatohepatitis

Interventions

BI 3804379
Placebo matching BI 3804379

Brief summary

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PKs) of BI 3804379 in healthy male and female participants and in stable patients with advanced liver fibrosis due to MASH following administration of single rising doses and administration of multiple rising doses.

Full record on ClinicalTrials.gov ↗

Change timeline

7 recorded · latest 1 Apr 2026

Completion date move · 3

Enrollment change · 2

Status change · 2

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

Phase 1SuspendedNCT07395258 ↗

Primary completion: Feb 2028; estimated
Enrollment: 60; estimated
Start: Apr 2026; Boehringer Ingelheim

Conditions

Solid Tumors

Interventions

BI 3923948
Ezabenlimab

Brief summary

This study is open to adults aged 18 and over or above legal age with different types of recurrent advanced cancer (solid tumors) that have spread to other parts of the body and that are accessible for injection and biopsy. This is a study for people for whom previous treatment was not successful or no treatment…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 May 2026

Status change · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

Phase 3RecruitingNCT06424288 ↗

Primary completion: May 2028; estimated
Enrollment: 6,000; estimated
Start: Jun 2024; Boehringer Ingelheim

Conditions

Heart Failure

Interventions

vicadrostat
empagliflozin
placebo

Brief summary

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jul 2025

Completion date move · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab

Phase 1RecruitingNCT07607678 ↗

Primary completion: Jun 2028; estimated
Enrollment: 60; estimated
Start: May 2026; Boehringer Ingelheim

Conditions

Advanced Solid Cancer
Metastatic Solid Cancer

Interventions

BI 3819026
Ezabenlimab (BI 754091)

Brief summary

This study is open to adults with advanced cancer. The purpose of this study is to find the highest dose of BI 3819026 that people with advanced cancer can tolerate when taken alone and together with ezabenlimab. BI 3819026 and ezabenlimab are study medicines that may fight cancer. Participants first receive one…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

Phase 3RecruitingNCT07107945 ↗

Primary completion: Jun 2028; estimated
Enrollment: 120; estimated
Start: Dec 2025; Boehringer Ingelheim

Conditions

Chronic Kidney Disease

Interventions

Empagliflozin
Placebo

Brief summary

This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medicine called empagliflozin helps children and adolescents with CKD. Other goals of the study are to find out how empagliflozin is tolerated and handled by the body in children and adolescents…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jan 2026

Status change · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

Phase 3RecruitingNCT07472517 ↗

Primary completion: Sept 2028; estimated
Enrollment: 670; estimated
Start: Apr 2026; Boehringer Ingelheim

Conditions

Small Cell Lung Cancer (SCLC)
Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Interventions

obrixtamig
atezolizumab
carboplatin
etoposide

Brief summary

This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival when compared to standard treatment alone. Obrixtamig is an antibody-like…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 May 2026

Status change · 1

Track Boehringer Ingelheim drugs to see every change the night it lands.

Track nerandomilast